Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals
Stephen L. Abrams, Kvin Lertpiriyapong, Li V. Yang, et al.
Advances in Biological Regulation (2018) Vol. 69, pp. 16-34
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Dimitrios Stefanoudakis, Maximos Frountzas, Dimitriοs Schizas, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 2827-2844
Open Access | Times Cited: 23
Decoding pancreatic cancer: key risk factors across genetics and lifestyle
Rohit Sharma, Rashmi Ghosh, Sourabh Kumar, et al.
Expert Review of Molecular Diagnostics (2025), pp. 1-5
Closed Access | Times Cited: 1
Sulforaphane as anticancer agent: A double-edged sword? Tricky balance between effects on tumor cells and immune cells
Jie Liang, Gertrud Maria Hänsch, Katrin Hübner, et al.
Advances in Biological Regulation (2018) Vol. 71, pp. 79-87
Closed Access | Times Cited: 62
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
James A. McCubrey, Li V. Yang, Stephen L. Abrams, et al.
Cells (2022) Vol. 11, Iss. 14, pp. 2155-2155
Open Access | Times Cited: 30
Multifunctional GQDs for receptor targeting, drug delivery, and bioimaging in pancreatic cancer
Monu Kumar Shukla, Arpana Parihar, Chandrabose Karthikeyan, et al.
Nanoscale (2023) Vol. 15, Iss. 36, pp. 14698-14716
Closed Access | Times Cited: 17
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells
Stephen L. Abrams, Matilde Y. Follo, Linda S. Steelman, et al.
Advances in Biological Regulation (2018) Vol. 71, pp. 172-182
Closed Access | Times Cited: 42
The Effects of Plumbagin on Pancreatic Cancer: A Mechanistic Network Pharmacology Approach
Qijin Pan, Rui Zhou, Min Su, et al.
Medical Science Monitor (2019) Vol. 25, pp. 4648-4654
Open Access | Times Cited: 40
Effects of Berberine against Pancreatitis and Pancreatic Cancer
Filip Vlavcheski, Eric J. O’Neill, Filip Gagacev, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8630-8630
Open Access | Times Cited: 22
Advancing Targeted Therapies in Pancreatic Cancer: Leveraging Molecular Aberrations for Therapeutic Success
Tanvi Gupta, Mohd Murtaza
Progress in Biophysics and Molecular Biology (2025)
Closed Access
Pathway-specific genomic alterations in pancreatic cancer across diverse cohorts
Cecilia Monge, Brigette Waldrup, Francisco J. Carranza-Chávez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells
Shaw M. Akula, Saverio Candido, Massimo Libra, et al.
Advances in Biological Regulation (2019) Vol. 73, pp. 100633-100633
Open Access | Times Cited: 35
ABCC3 is a novel target for the treatment of pancreatic cancer
Aleksandra Adamska, Riccardo Ferro, Rossano Lattanzio, et al.
Advances in Biological Regulation (2019) Vol. 73, pp. 100634-100634
Closed Access | Times Cited: 28
Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential
Alice Domenichini, Jeanne S. Edmands, Aleksandra Adamska, et al.
Advances in Biological Regulation (2019) Vol. 72, pp. 63-77
Closed Access | Times Cited: 23
TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
Shaw M. Akula, Peter P. Ruvolo, James A. McCubrey
Aging (2020) Vol. 12, Iss. 3, pp. 2777-2797
Open Access | Times Cited: 23
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
William H. Chappell, Saverio Candido, Stephen L. Abrams, et al.
Aging (2020) Vol. 12, Iss. 11, pp. 10194-10210
Open Access | Times Cited: 23
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
Stephen L. Abrams, Przemysław Duda, Shaw M. Akula, et al.
Cells (2022) Vol. 11, Iss. 5, pp. 794-794
Open Access | Times Cited: 13
An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma
Amy Makler, Ramaswamy Narayanan, Waseem Asghar
Biosensors (2022) Vol. 12, Iss. 10, pp. 831-831
Open Access | Times Cited: 13
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif
Investigational New Drugs (2023) Vol. 41, Iss. 4, pp. 587-595
Closed Access | Times Cited: 6
CirculatingTP53mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
Fleur van der Sijde, Zakia Azmani, Marc G. Besselink, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13, pp. 175883592110337-175883592110337
Open Access | Times Cited: 12
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties
James A. McCubrey, Akshaya K. Meher, Shaw M. Akula, et al.
Aging (2022) Vol. 14, Iss. 8, pp. 3365-3386
Open Access | Times Cited: 8
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals
Saverio Candido, Stephen L. Abrams, Linda S. Steelman, et al.
Advances in Biological Regulation (2019) Vol. 72, pp. 22-40
Closed Access | Times Cited: 11
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells
Shaw M. Akula, Saverio Candido, Stephen L. Abrams, et al.
Advances in Biological Regulation (2019) Vol. 75, pp. 100672-100672
Closed Access | Times Cited: 10
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
Bayan Al-Share, Nour Hammad, Maria Diab
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 1, pp. 355-371
Closed Access | Times Cited: 9
APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
James A. McCubrey, Stephen L. Abrams, Linda S. Steelman, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 276-276
Open Access | Times Cited: 6
Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
Tania Maffucci, Marco Falasca
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7198-7198
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top